Current Clinical Application of Mesenchymal Stem Cells in the Treatment of Severe COVID-19 Patients: Review

References

• Liu S, Peng D, Qiu H, et al. Mesenchymal stem cells as a potential therapy for COVID-19. Stem Cell Res Ther. 2020;11(1):1–4. doi:10.1186/s13287-020-01678-8
   PubMed Web of Science ®Google Scholar
• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269. doi:10.1038/s41586-020-2008-3
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi:10.1038/s41586-020-2012-7
   PubMed Web of Science ®Google Scholar
• World Health Organization. Coronavirus disease (COVID-19) situation dashboard. World Health Organization website. Available from: https://who.sprinklr.com/. Accessed April 17, 2020.
   Google Scholar
• Metcalfe SM. Mesenchymal stem cells and management of COVID-19 pneumonia. Med Drug Discov. 2020;5:100019. doi:10.1016/j.medidd.2020.100019
   PubMedGoogle Scholar
• Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—the latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264–266. doi:10.1016/j.ijid.2020.01.009
   PubMed Web of Science ®Google Scholar
• Abraham A, Krasnodembskaya A. Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem Cells Transl Med. 2020;9(1):28–38. doi:10.1002/sctm.19-0205
   PubMed Web of Science ®Google Scholar
• Shah TG, Predescu D, Predescu S. Mesenchymal stem cells-derived extracellular vesicles in acute respiratory distress syndrome: a review of current literature and potential future treatment options. Clin Transl Med. 2019;8(1):1–6. doi:10.1186/s40169-019-0242-9
   Web of Science ®Google Scholar
• Jabbari N, Nawaz M, Rezaie J. Ionizing radiation increases the activity of exosomal secretory pathway in MCF-7 human breast cancer cells: a possible way to communicate resistance against radiotherapy. Int J Mol Sci. 2019;20(15):3649. doi:10.3390/ijms20153649
   Web of Science ®Google Scholar
• Martin-Rufino JD, Espinosa-Lara N, Osugui L, et al. Targeting the immune system with mesenchymal stromal cell-derived extracellular vesicles: what is the Cargo’s mechanism of action? Front Bioengineer Biotechnol. 2019;7:308. doi:10.3389/fbioe.2019.00308
   Web of Science ®Google Scholar
• Joo HS, Suh JH, Lee HJ, Bang ES, Lee JM. Current knowledge and future perspectives on mesenchymal stem cell-derived exosomes as a new therapeutic agent. Int J Mol Sci. 2020;21(3):727. doi:10.3390/ijms21030727
   PubMed Web of Science ®Google Scholar
• Belouzard S, Millet JK, Licitra BN, et al. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4(6):1011–1033. doi:10.3390/v4061011
   PubMed Web of Science ®Google Scholar
• Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–1976. doi:10.1056/NEJMoa030747
   PubMed Web of Science ®Google Scholar
• De Groot RJ, Baker SC, Baric RS, et al. Commentary: middle East respiratory syndrome coronavirus (mers-cov): announcement of the coronavirus study group. J Virol. 2013;87(14):7790–7792. doi:10.1128/JVI.01244-13
   PubMed Web of Science ®Google Scholar
• Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490–502. doi:10.1016/j.tim.2016.03.003
   PubMed Web of Science ®Google Scholar
• Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. In: Coronaviruses. Springer; 2015:1–23.
   Google Scholar
• Whittaker GR, Millet JK. Biochemical Characterization of Middle East Respiratory Syndrome Coronavirus Spike Protein Proteolytic Processing, in MERS Coronavirus. Springer; 2020:21–37.
   Google Scholar
• Wu C, Liu Y, Yang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10(5):766–788. doi:10.1016/j.apsb.2020.02.008
   PubMed Web of Science ®Google Scholar
• Alanagreh LA, Alzoughool F, Atoum M. The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms. Pathogens. 2020;9(5):331. doi:10.3390/pathogens9050331
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni Z-Y, Hu Y, et al. Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032
   PubMed Web of Science ®Google Scholar
• Lauer SA, Grantz KH, Bi Q, et al. The incubation period of Coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172(9):577–582. doi:10.7326/M20-0504
   PubMed Web of Science ®Google Scholar
• Han Y, Li X, Zhang Y. Mesenchymal stem cells for regenerative medicine. Cells. 2019;8(8):886.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
   PubMed Web of Science ®Google Scholar
• Pan Y, Zhang D, Yang P, et al. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis. 2020;20(4):411–412. doi:10.1016/S1473-3099(20)30113-4
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhou X, Qiu Y, et al. Clinical characteristics of 82 cases of death from COVID-19. PloS One. 2020;15(7):e0235458.
   PubMed Web of Science ®Google Scholar
• Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–2629. doi:10.1172/JCI137244
   PubMed Web of Science ®Google Scholar
• Diao B, Wang C, Tan Y, et al. Reduction and functional exhaustion of T cells in patients with Coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827. doi:10.3389/fimmu.2020.00827
   PubMed Web of Science ®Google Scholar
• Yang Y, Shen C, Li J, et al. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol. 2020;146(1):119–127.e4. doi:10.1016/j.jaci.2020.04.027
   PubMed Web of Science ®Google Scholar
• Tian S, Hu W, Niu L, et al. Pulmonary pathology of early-phase 2019 novel Coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15(5):700–704. doi:10.1016/j.jtho.2020.02.010
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:10.1016/S2213-2600(20)30076-X
   PubMed Web of Science ®Google Scholar
• Park WB, Kwon NJ. Virus isolation from the first patient with SARS-CoV-2 in Korea. J Korean Med Sci. 2020;35(7):e84.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhou P, Wei Y, et al. Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19. Ann Intern Med. 2020;172(9):629–632. doi:10.7326/M20-0533
   PubMed Web of Science ®Google Scholar
• Golchin A, Farahany TZ. Biological products: cellular therapy and FDA approved products. Stem Cell Rev Rep. 2019;15(2):166–175. doi:10.1007/s12015-018-9866-1
   PubMed Web of Science ®Google Scholar
• Golchin A, Farahany TZ, Khojasteh A, et al. The clinical trials of mesenchymal stem cell therapy in skin diseases: an update and concise review. Curr Stem Cell Res Ther. 2019;14(1):22–33. doi:10.2174/1574888X13666180913123424
   PubMed Web of Science ®Google Scholar
• Yıldız Gülhan P. The role of mesenchymal stem cells in COVID-19 treatment. Tuberk Toraks. 2020;68(4):430–436. doi:10.5578/tt.69770
   Web of Science ®Google Scholar
• Darwish I, Mubareka S, Liles WC. Immunomodulatory therapy for severe influenza. Expert Rev Anti Infect Ther. 2011;9(7):807–822. doi:10.1586/eri.11.56
   PubMed Web of Science ®Google Scholar
• Liang B, Chen J, Li T, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine. 2020;99(31):e21429.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID‐19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020;395(10229):1033. doi:10.1016/S0140-6736(20)30628-0
   PubMed Web of Science ®Google Scholar
• Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216. doi:10.14336/AD.2020.0228
   PubMed Web of Science ®Google Scholar
• Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician. 2020;23(2):E71–e83.
   PubMed Web of Science ®Google Scholar
• Court AC, Le-gatt A, Luz-Crawford P. Mitochondrial transfer from MSCs to T cells induces Treg differentiation and restricts inflammatory response. EMBO Rep. 2020;21(2):e48052.
   Web of Science ®Google Scholar
• Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med. 2012;18(5):759–765. doi:10.1038/nm.2736
   PubMed Web of Science ®Google Scholar
• Khoury M, Cuenca J, Cruz FF, et al. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J. 2020;55(6):2000858. doi:10.1183/13993003.00858-2020
   PubMed Web of Science ®Google Scholar
• Li Y, Xu J, Shi W, et al. Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice. Stem Cell Res Ther. 2016;7(1):1–11. doi:10.1186/s13287-016-0395-z
   Web of Science ®Google Scholar
• Khatri M, Richardson LA, Meulia T. Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther. 2018;9(1):1–13. doi:10.1186/s13287-018-0774-8
   PubMed Web of Science ®Google Scholar
• Orleans LA, Is Vice H, Manchikanti L. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically ill COVID-19 patients: the case for compassionate use. Pain Physician. 2020;23:E71–E83.
   PubMed Web of Science ®Google Scholar
• Shetty AK. Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia. Aging Dis. 2020;11(2):462. doi:10.14336/AD.2020.0301
   PubMed Web of Science ®Google Scholar
• Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol. 2005;33:145–152. doi:10.1165/rcmb.2004-0330OC
   PubMed Web of Science ®Google Scholar
• Loi R, Beckett T, Goncz KK, et al. Limited Restoration of cystic fibrosis lung epithelium in vivo with adult bone marrow–derived cells. Am J Respir Crit Care Med. 2006;173(2):171–179. doi:10.1164/rccm.200502-309OC
   PubMed Web of Science ®Google Scholar
• Tsai TH, Lieu AS, Hwang SL, et al. A comparative study of the patients with bilateral or unilateral chronic subdural hematoma: precipitating factors and postoperative outcomes. J Trauma Acute Care Surg. 2010;68(3):571–575. doi:10.1097/TA.0b013e3181a5f31c
   Web of Science ®Google Scholar
• Mei SHJ, McCarter SD, Deng Y, et al. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med. 2007;4(9):e269. doi:10.1371/journal.pmed.0040269
   PubMed Web of Science ®Google Scholar
• Shyamsundar M, McAuley DF, Ingram RJ, et al. Keratinocyte growth factor promotes epithelial survival and resolution in a human model of lung injury. Am J Respir Crit Care Med. 2014;189(12):1520–1529. doi:10.1164/rccm.201310-1892OC
   PubMed Web of Science ®Google Scholar
• Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20(7):389–391.
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen QH, Liu AR, et al. Synergism of MSC-secreted HGF and VEGF in stabilising endothelial barrier function upon lipopolysaccharide stimulation via the Rac1 pathway. Stem Cell Res Ther. 2015;6:250. doi:10.1186/s13287-015-0257-0
   Web of Science ®Google Scholar
• Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–1687. doi:10.1093/cvr/cvaa106
   PubMed Web of Science ®Google Scholar
• Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18(5):683–692. doi:10.1089/scd.2008.0253
   PubMed Web of Science ®Google Scholar
• Feng G, Shi L, Huang T, et al. Human umbilical cord mesenchymal stromal cell treatment of severe COVID-19 patients: a 3-month follow-up study following hospital discharge. Stem Cells Dev. 2021;30(15):773–781. doi:10.1089/scd.2021.0015
   PubMed Web of Science ®Google Scholar
• Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord-derived mesenchymal stem cells for COVID-19 patients with acute respiratory distress syndrome (ARDS). CellR4 Repair Replace Regen Reprog. 2020;8:660–673.
   Google Scholar
• Matthay MA, Calfee CS, Zhuo H, et al. Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med. 2019;7(2):154–162. doi:10.1016/S2213-2600(18)30418-1
   PubMed Web of Science ®Google Scholar
• Bilgir O, Bilgir F, Calan M, et al. Comparison of pre- and post-levothyroxine high-sensitivity c-reactive protein and fetuin-a levels in subclinical hypothyroidism. Clinics (Sao Paulo). 2015;70(2):97–101. doi:10.6061/clinics/2015(02)05
   Web of Science ®Google Scholar
• Aloisio E, Chibireva M, Serafini L, et al. A comprehensive appraisal of laboratory biochemistry tests as major predictors of COVID-19 severity. Arch Pathol Lab Med. 2020;144(12):1457–1464. doi:10.5858/arpa.2020-0389-SA
   PubMed Web of Science ®Google Scholar
• Tang L, Jiang Y, Zhu M, et al. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front Med. 2020;14(5):664–673. doi:10.1007/s11684-020-0810-9
   Web of Science ®Google Scholar
• Shu L, Niu C, Li R, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):361. doi:10.1186/s13287-020-01875-5
   PubMed Web of Science ®Google Scholar
• Zhao XY, XuXX, Yin HS, et al. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. BMC Infect Dis. 2020;20(1):311. doi:10.1186/s12879-020-05010-w
   PubMed Web of Science ®Google Scholar
• Cho KA, Woo S, Seoh J, et al. Mesenchymal stem cells restore CCl 4-induced liver injury by an antioxidative process. Cell Biol Int. 2012;36(12):1267–1274. doi:10.1042/CBI20110634
   Web of Science ®Google Scholar
• Zhang Y, Ding J, Ren S, et al. Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. Stem Cell Res Ther. 2020;11(1):207.
   Web of Science ®Google Scholar
• Li Y,Xu Y, Wu HM, Yang J, Yang LH, Yue-Meng W. Umbilical cord-derived mesenchymal stem cell transplantation in hepatitis B virus-related acute-on-chronic liver failure treated with plasma exchange and entecavir: a 24-month prospective study. Stem Cell Rev Rep. 2016;12(6):645–653. doi:10.1007/s12015-016-9683-3
   Google Scholar
• Qian JY, Wang B, Liu BC. Acute kidney injury in the 2019 novel Coronavirus disease. Kidney Dis (Basel). 2020;323:1–6.
   PubMed Web of Science ®Google Scholar
• Brienza N, Puntillo F, Romagnoli S, et al. Acute kidney injury in Coronavirus disease 2019 infected patients: a meta-analytic study. Blood Purif. 2021;50(1):35–41. doi:10.1159/000509274
   Web of Science ®Google Scholar
• Li Y, Hu Y, Yu J, et al. Retrospective analysis of laboratory testing in 54 patients with severe- or critical-type 2019 novel coronavirus pneumonia. Lab Invest. 2020;100(6):794–800. doi:10.1038/s41374-020-0431-6
   PubMed Web of Science ®Google Scholar
• Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829–838. doi:10.1016/j.kint.2020.03.005
   PubMed Web of Science ®Google Scholar
• Herrera MB, Bussolati B, Bruno S, et al. Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury. Kidney Int. 2007;72(4):430–441. doi:10.1038/sj.ki.5002334
   PubMed Web of Science ®Google Scholar
• Ninichuk V, Gross O, Segerer S, et al. Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int. 2006;70(1):121–129. doi:10.1038/sj.ki.5001521
   Web of Science ®Google Scholar
• Tao J, Nie Y, Wu H, et al. Umbilical cord blood-derived mesenchymal stem cells in treating a critically ill COVID-19 patient. J Infect Dev Ctries. 2020;14(10):1138–1145. doi:10.3855/jidc.13081
   Web of Science ®Google Scholar
• Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020;5(1):172.
   PubMed Web of Science ®Google Scholar